Why the Deltoid Muscle is Contraindicated for Benzathine Penicillin G Injection
The deltoid muscle is absolutely contraindicated for intramuscular benzathine penicillin G injection due to the high risk of severe neurovascular complications, including permanent paralysis, gangrene requiring amputation, and Nicolau syndrome. 1
Primary Safety Concerns
The FDA drug label for benzathine penicillin G explicitly warns against deltoid administration due to documented catastrophic outcomes:
Severe neurovascular damage has been reported following deltoid injections, including transverse myelitis with permanent paralysis, gangrene requiring digit and limb amputation, and tissue necrosis consistent with Nicolau syndrome. 1
Inadvertent intravascular administration (intra-arterial injection or injection immediately adjacent to arteries) in the deltoid area has resulted in immediate pallor, mottling, cyanosis, severe edema, and compartment syndrome requiring fasciotomy. 1
These severe complications have occurred most frequently in infants and small children, but adults are also at risk. 1
Anatomical and Pharmacological Rationale
The deltoid muscle presents unique anatomical hazards for benzathine penicillin G:
The deltoid region has high vascularity with the axillary nerve and posterior circumflex humeral artery located approximately 8-9 cm from the mid-acromial point, creating significant risk of neurovascular injury. 2
The deltoid muscle has insufficient muscle mass compared to the gluteal region, increasing the risk of inadvertent intravascular injection even with standard injection techniques. 3
Case reports document that transverse myelitis and permanent spinal cord injury have occurred following deltoid benzathine penicillin injections using standard techniques without evident blood return on aspiration. 3
FDA-Mandated Injection Sites
The FDA drug label specifies only two acceptable sites for benzathine penicillin G:
Administer by deep intramuscular injection ONLY in the upper, outer quadrant of the buttock (dorsogluteal) or the ventrogluteal site. 1
The anterolateral thigh is explicitly NOT recommended due to reports of quadriceps femoris fibrosis and atrophy following repeated injections, plus the high vascularity of this region. 1
Clinical Context: Syphilis Treatment
For syphilis treatment specifically, the guidelines consistently recommend gluteal administration:
HIV-infected and HIV-uninfected persons with early-stage syphilis should receive 2.4 million units of benzathine penicillin G as a single intramuscular injection, administered in the gluteal region. 4, 5
Late-latent syphilis requires three weekly intramuscular injections of 2.4 million units, all administered in the gluteal region. 5, 6
Critical Safety Warning
The FDA mandates that prompt consultation with an appropriate specialist is indicated if ANY evidence of compromised blood supply occurs at, proximal to, or distal to the injection site. 1
Cardiorespiratory arrest and death have been reported with inadvertent intravenous administration of benzathine penicillin G, emphasizing the critical importance of proper injection technique and site selection. 1
Common Pitfall to Avoid
Do not confuse benzathine penicillin G injection site recommendations with those for other intramuscular medications. While the deltoid is acceptable for many vaccines and medications (including influenza vaccine in older children and adults 7), benzathine penicillin G has unique pharmacological properties—extremely low solubility and slow release from injection sites 1—that make deltoid administration unacceptably dangerous. The consequences of inadvertent intravascular injection are catastrophic and irreversible. 1, 3, 8